For the quarter ending 2025-09-30, TGTX had -$55,032K decrease in cash & cash equivalents over the period. -$23,233K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income | 390,895 | 33,247 |
| Loss on extinguishment of debt | 0 | - |
| Noncash stock compensation expense | 17,686 | 31,333 |
| Depreciation and amortization | 17 | 21 |
| Amortization of premium (discount) on investment securities | 786 | 2,619 |
| Amortization of debt issuance costs | 304 | 608 |
| Amortization of leasehold interest | 45 | 94 |
| Deferred income taxes | -366,627 | - |
| Noncash change in lease liability and right of use asset | 431 | 885 |
| Change in fair value of equity investments | 420 | -285 |
| Change in fair value of notes payable | -14 | -149 |
| Increase in inventory | -8,695 | 42,710 |
| Increase in other current assets | 30,632 | 9,887 |
| Increase in accounts receivable | 33,868 | 102,331 |
| Increase in accounts payable and accrued expenses | -17,280 | 71,150 |
| Decrease in lease liabilities | -519 | -1,061 |
| (decrease) increase in other current liabilities | -277 | -2,370 |
| Increase in deferred revenue | 9,169 | 1,927 |
| Net cash used in operating activities | -23,153 | -21,279 |
| Proceeds from maturity of held-to-maturity securities | 77,750 | 129,750 |
| Investment in held-to-maturity securities | 31,307 | 145,359 |
| Investment in equity investments | 0 | 1,250 |
| Purchases of property, plant and equipment | 80 | 67 |
| Net cash provided by (used in) investing activities | 46,363 | -16,926 |
| Payment of loan payable | 0 | - |
| Proceeds from exercise of options | 0 | 453 |
| Proceeds from debt financings | 0 | - |
| Financing costs paid | 0 | - |
| Purchase of treasury stock | 78,242 | 12,998 |
| Net cash (used in) provided by financing activities | -78,242 | -12,545 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -55,032 | -50,750 |
| Cash and cash equivalents at beginning of period | 181,192 | - |
| Cash and cash equivalents at end of period | 75,410 | - |
TG THERAPEUTICS, INC. (TGTX)
TG THERAPEUTICS, INC. (TGTX)